Small-Cell Lung Cancer Drug Market Will More Than Double to Over $684 Million in 2017

... of Genentech/Roche/Chugai's Avastin and Celgene's amrubicin (currently marketed in Japan as Calsed by Nippon K...s a first-line add-on to standard chemotherapy and amrubicin as a second-line therapy will drive robust 22 perc...ore, despite the impressive sales that Avastin and amrubicin will add to the market, these therapies will have ...

Amrubicin Shows Encouraging Results for Small Cell Lung Cancer Treatment

...n terms of response rate and safety when comparing amrubicin to the current treatment standard, topotecan, in s...mall cell lung cancer." The trial compares amrubicin and topotecan in patients with ED-SCLC that initia... participants are randomized 2:1 to receive either amrubicin (40 mg/m2 via 5- min.infusion daily x 3 days) or t...

Amrubicin in Medical Technology

Pharmion's Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer

Interim analysis of Phase 2 clinical data presented at the 2007 Chemotherapy Foundation Symposium BOULDER, Colo., Nov. 9 /PRNewswire-FirstCall/ -- Pharmion Corporation (Nasdaq: PHRM ) today released interim findings from its Phase 2 trial of Amrubicin in second-line chem...

Pharmion Initiates Pivotal Phase 3 Study of Amrubicin in Small Cell Lung Cancer

BOULDER, Colo., Oct. 17 /PRNewswire-FirstCall/ -- Pharmion Corporation (Nasdaq: PHRM ) today announced the initiation of an international pivotal Phase 3 clinical trial evaluating amrubicin, the Company's third-generation synthetic anthracycline, in the treatment of second-line small cell lun...

Pharmion's Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer

Interim Analysis of Phase 2 Clinical Data Published at the American Society of Clinical Oncology 43rd Annual Meeting CHICAGO, June 04, 2007 /PRNewswire-FirstCall/ -- Pharmion Corporation today released interim findings from its Phase II, multi-center clinical study of Amrubicin, the company's thir...

Pharmion to Present Clinical Data on Commercial and Pipeline Products at 2007 American Society of Clinical Oncology (ASCO) Meeting

...ate Cancer." Interim data on a Phase II study of amrubicin appears in the ASCO 2007 conference publication, a... June 4, 2007; 11:00-11:15am; Arie Crown Theater amrubicin A randomized phase II trial of amrubicin vs. Topotecan as second-line treatment in extensiv...